tolazoline has been researched along with Hyaline Membrane Disease in 11 studies
Tolazoline: A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn.
tolazoline : A member of the class of imidazoles that is 4,5-dihydro-1H-imidazole substituted by a benzyl group.
Hyaline Membrane Disease: A respiratory distress syndrome in newborn infants, usually premature infants with insufficient PULMONARY SURFACTANTS. The disease is characterized by the formation of a HYALINE-like membrane lining the terminal respiratory airspaces (PULMONARY ALVEOLI) and subsequent collapse of the lung (PULMONARY ATELECTASIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "The condition of a neonate with severe persistent pulmonary hypertension who became severely hypoxic and acidotic despite intensive conventional treatment improved dramatically after endotracheal administration of tolazoline." | 7.69 | Endotracheal tolazoline for severe persistent pulmonary hypertension of the newborn. ( Bridson, JM; Gibbs, JL; Welch, JC, 1995) |
| "Ten critically-ill preterm infants with severe hyaline membrane disease received tolazoline because of persistent hypoxemia refractory to the administration of 100% oxygen and mechanical ventilation." | 7.68 | Effect of tolazoline on persistent hypoxemia in severe hyaline membrane disease. ( Han, DG; Lee, C; Namgung, R; Park, KI, 1990) |
| "Tolazoline hydrochloride was given as a pulmonary vasodilator to 20 preterm infants with severe hyaline membrane disease requiring mechanical ventilation who developed persistent severe hypoxaemia." | 7.66 | Effect of tolazoline in severe hyaline membrane disease. ( McIntosh, N; Walters, RO, 1979) |
| "Tolazoline treatment of neonates has been reported since 1965." | 5.27 | Oliguria and tolazoline pharmacokinetics in the newborn. ( Daniel, CH; Kendig, JW; Ward, RM; Wood, MA, 1986) |
| "We describe a premature baby with X pentasomy, having a severe pulmonary hypertension secondary to perinatal asphyxia and hyaline membrane disease which appeared to be refractory to conventional treatments (hyperventilation, tolazoline, prostacyclin)." | 3.69 | [Efficacy of magnesium in a case of neonatal pulmonary hypertension refractory to the usual therapies]. ( Benettoni, A; Ciana, G; Colonna, F; Giorgi, R, 1994) |
| "The condition of a neonate with severe persistent pulmonary hypertension who became severely hypoxic and acidotic despite intensive conventional treatment improved dramatically after endotracheal administration of tolazoline." | 3.69 | Endotracheal tolazoline for severe persistent pulmonary hypertension of the newborn. ( Bridson, JM; Gibbs, JL; Welch, JC, 1995) |
| "Ten critically-ill preterm infants with severe hyaline membrane disease received tolazoline because of persistent hypoxemia refractory to the administration of 100% oxygen and mechanical ventilation." | 3.68 | Effect of tolazoline on persistent hypoxemia in severe hyaline membrane disease. ( Han, DG; Lee, C; Namgung, R; Park, KI, 1990) |
| "Tolazoline hydrochloride was given as a pulmonary vasodilator to 20 preterm infants with severe hyaline membrane disease requiring mechanical ventilation who developed persistent severe hypoxaemia." | 3.66 | Effect of tolazoline in severe hyaline membrane disease. ( McIntosh, N; Walters, RO, 1979) |
| " Some infants with severe, persistent pulmonary hypertension who were receiving an intravascular infusion of tolazoline and infants with mean arterial blood pressures more than 2." | 3.66 | Transcutaneous oxygen tension in sick infants. ( Gregory, GA; Peabody, JL; Tooley, WH; Willis, MM, 1978) |
| "Tolazoline treatment of neonates has been reported since 1965." | 1.27 | Oliguria and tolazoline pharmacokinetics in the newborn. ( Daniel, CH; Kendig, JW; Ward, RM; Wood, MA, 1986) |
| "Thirty-nine critically ill infants with pulmonary disease received tolazoline because of severe hypoxemia refractory to administration of 100% O2 and mechanical ventilation." | 1.26 | Refractory hypoxemia associated with neonatal pulmonary disease: the use and limitations of tolazoline. ( Ariagno, RL; Beets, CL; Darnall, RA; Johnson, JD; Kasting, DS; Malachowski, N; Stevenson, DK; Sunshine, P, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (72.73) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| COTTON, EK | 1 |
| Colonna, F | 1 |
| Giorgi, R | 1 |
| Ciana, G | 1 |
| Benettoni, A | 1 |
| Welch, JC | 1 |
| Bridson, JM | 1 |
| Gibbs, JL | 1 |
| Omeñaca, F | 1 |
| Navarro, C | 1 |
| Barrio, C | 1 |
| Pérez Rodríguez, J | 1 |
| García Frías, E | 1 |
| Quero, J | 1 |
| Moreno, F | 1 |
| McIntosh, N | 1 |
| Walters, RO | 1 |
| Stevenson, DK | 1 |
| Kasting, DS | 1 |
| Darnall, RA | 1 |
| Ariagno, RL | 1 |
| Johnson, JD | 1 |
| Malachowski, N | 1 |
| Beets, CL | 1 |
| Sunshine, P | 1 |
| Brooks, G | 1 |
| Backes, CR | 1 |
| Peabody, JL | 1 |
| Gregory, GA | 1 |
| Willis, MM | 1 |
| Tooley, WH | 1 |
| Park, KI | 1 |
| Namgung, R | 1 |
| Lee, C | 1 |
| Han, DG | 1 |
| Kiszel, J | 1 |
| Seri, I | 1 |
| Machay, T | 1 |
| Ward, RM | 1 |
| Daniel, CH | 1 |
| Kendig, JW | 1 |
| Wood, MA | 1 |
11 other studies available for tolazoline and Hyaline Membrane Disease
| Article | Year |
|---|---|
THE USE OF PRISCOLINE IN THE TREATMENT OF THE HYPOPERFUSION SYNDROME.
Topics: Drug Therapy; Humans; Hyaline Membrane Disease; Infant; Infant, Newborn; Ischemia; Pulmonary Circula | 1965 |
[Efficacy of magnesium in a case of neonatal pulmonary hypertension refractory to the usual therapies].
Topics: Asphyxia Neonatorum; Epoprostenol; Female; Humans; Hyaline Membrane Disease; Hypertension, Pulmonary | 1994 |
Endotracheal tolazoline for severe persistent pulmonary hypertension of the newborn.
Topics: Acidosis; Administration, Topical; Humans; Hyaline Membrane Disease; Hypertension, Pulmonary; Hypoxi | 1995 |
[Meconium aspiration syndrome with severe hypoxemia. Treatment with a pulmonary vasodilator (tolarzoline) (author's transl)].
Topics: Ductus Arteriosus, Patent; Female; Humans; Hyaline Membrane Disease; Hypertension, Pulmonary; Hypoxi | 1979 |
Effect of tolazoline in severe hyaline membrane disease.
Topics: Female; Humans; Hyaline Membrane Disease; Hypoxia; Infant, Newborn; Infant, Premature; Male; Oxygen; | 1979 |
Refractory hypoxemia associated with neonatal pulmonary disease: the use and limitations of tolazoline.
Topics: Carbon Dioxide; Humans; Hyaline Membrane Disease; Hypoxia; Infant, Newborn; Infant, Newborn, Disease | 1979 |
Usefulness of tolazoline in severe hypoxemia and acidosis complicating hyaline membrane disease: report of case.
Topics: Acidosis; Female; Humans; Hyaline Membrane Disease; Hypoxia; Infant, Newborn; Tolazoline | 1979 |
Transcutaneous oxygen tension in sick infants.
Topics: Blood Pressure; Electrodes; Evaluation Studies as Topic; Heart Defects, Congenital; Heart Rate; Huma | 1978 |
Effect of tolazoline on persistent hypoxemia in severe hyaline membrane disease.
Topics: Humans; Hyaline Membrane Disease; Hypoxia; Infant; Infant, Newborn; Infusions, Intravenous; Tolazoli | 1990 |
High-frequency oscillatory ventilation (HFOV) in the treatment of neonatal respiratory disturbances: case reports of two infants.
Topics: Carbon Dioxide; Humans; Humidity; Hyaline Membrane Disease; Infant, Newborn; Infant, Premature; Male | 1985 |
Oliguria and tolazoline pharmacokinetics in the newborn.
Topics: Animals; Anuria; Half-Life; Humans; Hyaline Membrane Disease; Hypertension, Pulmonary; Infant, Newbo | 1986 |